Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$5.26 USD
-0.13 (-2.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.25 -0.01 (-0.19%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Earnings News For TVTX
-
Travere: Q4 Earnings Snapshot
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Travere: Q3 Earnings Snapshot
-
Travere Therapeutics Reports Third Quarter 2023 Financial Results
-
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
-
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
-
Travere Therapeutics Reports Second Quarter 2023 Financial Results
-
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
-
Travere: Q1 Earnings Snapshot
-
Travere Therapeutics Reports First Quarter 2023 Financial Results
-
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Travere: Q4 Earnings Snapshot
-
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
-
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
-
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
-
Travere: Q3 Earnings Snapshot
-
Travere Therapeutics Reports Third Quarter 2022 Financial Results
-
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
-
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
-
Travere: Q2 Earnings Snapshot
-
Travere Therapeutics Reports Second Quarter 2022 Financial Results
-
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
-
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates